Hematopoiesis and leukemogenesis in mice expressing oncogenic Nras G12D from the endogenous locus

Blood

Volumn 117, Issue 6, 2011, Pages 2022-2032

  Li, Qing ^a,g   Haigis, Kevin M ^b   McDaniel, Andrew ^a   Harding Theobald, Emily ^a   Kogan, Scott C ^a,c   Akagi, Keiko ^d   Wong, Jasmine C Y ^a   Braun, Benjamin S ^a   Wolff, Linda ^e   Jacks, Tyler ^f   Shannon, Kevin ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAS PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCUS; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC TISSUE; LEUKEMOGENESIS; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE N RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL;

EID: 79951472496     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-280750     Document Type: Article

References (46)

1. Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science. 2001;294(5545):1299-1304. (Pubitemid 33063089)
2. Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell. 2007;129(5):865-877. (Pubitemid 46802708)
3. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459-465. (Pubitemid 37328850)
4. Mor A, Philips MR. Compartmentalized Ras/MAPK signaling. Annu Rev Immunol. 2006;24: 771-800.
5. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
6. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7(4):295-308. (Pubitemid 46480970)
7. Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta. 2002;1602(1): 23-45. (Pubitemid 34311898)
8. Potenza N, Vecchione C, Notte A, et al. Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice. EMBO Rep. 2005; 6(5):432-437. (Pubitemid 40767076)
9. Johnson L, Mercer K, Breenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001; 410:1111-1116. (Pubitemid 32391044)
10. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15(24):3243-3248. (Pubitemid 34008190)
11. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell. 2003;4(2):111-120. (Pubitemid 37040827)
12. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet. 2008;40(5):600-608. (Pubitemid 351601205)
13. Padua RA, Carter G, Hughes D, et al. RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. Leukemia. 1988;2(8):503-510.
14. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3):840-849. (Pubitemid 34525544)
15. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 2006; 107(10):3847-3853. (Pubitemid 43726786)
16. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106(6):2113-2119. (Pubitemid 41291728)
17. Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004;101(2): 597-602. (Pubitemid 38084682)
18. Chan IT, Kutok JL, Williams IR, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest. 2004;113(4):528-538. (Pubitemid 38542502)
19. Wolff L, Koller R, Hu X, Anver MR. A Moloney murine leukemia virus-based retrovirus with 4070A long terminal repeat sequences induces a high incidence of myeloid as well as lymphoid neoplasms. J Virol. 2003;77(8):4965-4971. (Pubitemid 36402845)
20. Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res. 2004;32(Database issue):D523-D527. (Pubitemid 38081713)
21. Dail M, Li Q, McDaniel A, et al. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A. 2010; 107(11):5106-5111.
22. Lauchle JO, Kim D, Le DT, et al. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature. 2009;461(7262): 411-414.
23. Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell. 2004; 119(3):431-443. (Pubitemid 39423844)
24. Van Meter ME, Diaz-Flores E, Archard JA, et al. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood. 2007;109(9): 3945-3952. (Pubitemid 46641747)
25. Zhang J, Liu Y, Beard C, et al. Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. Blood. 2007;109(12):5238-5241. (Pubitemid 46890543)
26. Zhang J, Socolovsky M, Gross AW, Lodish HF. Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system. Blood. 2003;102(12):3938-3946. (Pubitemid 37486974)
27. Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood. 2006;108(6):2041-2044. (Pubitemid 44395019)
28. Kogan SC, Lagasse E, Atwater S, et al. The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc Natl Acad Sci U S A. 1998; 95(20):11863-11868. (Pubitemid 28460505)
29. Wiesner SM, Jones JM, Hasz DE, Largaespada DA. Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse. Blood. 2005; 106(3):1054-1062. (Pubitemid 41076454)
30. Omidvar N, Kogan S, Beurlet S, et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res. 2007;67(24):11657-11667.
31. Kim WI, Matise I, Diers MD, Largaespada DA. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. Blood. 2009;113(5):1086-1096.
32. MacKenzie KL, Dolnikov A, Millington M, Shounan Y, Symonds G. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood. 1999; 93(6):2043-2056. (Pubitemid 29128508)
33. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood. 2006;108(7): 2349-2357. (Pubitemid 44497519)
34. Silvius JR. Mechanisms of Ras protein targeting in mammalian cells. J Membr Biol. 2002;190(2): 83-92. (Pubitemid 36930423)
35. Hancock JF. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol. 2003; 4(5):373-384. (Pubitemid 36565569)
36. Rocks O, Peyker A, Bastiaens PI. Spatio-temporal segregation of Ras signals: one ship, three anchors, many harbors. Curr Opin Cell Biol. 2006;18(4):351-357. (Pubitemid 44016056)
37. Abankwa D, Gorfe AA, Hancock JF. Ras nanoclusters: molecular structure and assembly. Semin Cell Dev Biol. 2007;18(5):599-607. (Pubitemid 350026427)
38. Tian T, Harding A, Inder K, Plowman S, Parton RG, Hancock JF. Plasma membrane nanoswitches generate high-fidelity Ras signal transduction. Nat Cell Biol. 2007;9(8):905-914. (Pubitemid 47190445)
39. Quinlan MP, Quatela SE, Philips MR, Settleman J. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol. 2008;28(8):2659-2674. (Pubitemid 351542366)
40. Kelly L, Clark J, Gilliland DG. Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications. Curr Opin Oncol. 2002;14(1): 10-18. (Pubitemid 34072957)
41. Farr CJ, Saiki RK, Erlich HA, McCormick F, Marshall CJ. Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci U S A. 1988;85(5):1629-1633. (Pubitemid 18070810)
42. Bashey A, Gill R, Levi S, et al. Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): implications for the role of N-ras mutation in AML pathogenesis. Blood. 1992;79(4):981-989.
43. Zhang Z, Wang Y, Vikis HG, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet. 2001;29(1):25-33. (Pubitemid 32801804)
44. To MD, Wong CE, Karnezis AN, Del Rosario R, Di Lauro R, Balmain A. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet. 2008;40(10):1240-1244.
45. Diaz R, Lue J, Mathews J, et al. Inhibition of Ras oncogenic activity by Ras protooncogenes. Int J Cancer. 2005;113(2):241-248. (Pubitemid 39628314)
46. Scholl C, Frohling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009;137(5):821-834.